# Topical rVA576 for Treatment of Atopic Keratoconjunctivitis

> **NCT04037891** · PHASE1,PHASE2 · TERMINATED · sponsor: **AKARI Therapeutics** · enrollment: 12 (actual)

## Conditions studied

- Keratoconjunctivitis, Atopic
- Keratoconjunctivitis, Vernal
- Conjunctivitis, Allergic

## Interventions

- **DRUG:** rVA576
- **OTHER:** Placebo
- **DRUG:** rVA576

## Key facts

- **NCT ID:** NCT04037891
- **Lead sponsor:** AKARI Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-04
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-04-30
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The trial has terminated early due to the disruptions caused by the ongoing COVID-19 pandemic. The decision was not related to any efficacy, safety or clinical concerns regarding rVA576.
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04037891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04037891, "Topical rVA576 for Treatment of Atopic Keratoconjunctivitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04037891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*